Patents by Inventor John J. Puisis

John J. Puisis has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • TREATMENT OF PRIMARY BILIARY CHOLANGITIS (PBC) WITH TOLERIZING NANOPARTICLES
    Publication number: 20240408186
    Abstract: The present disclosure relates to methods of treating Primary Biliary Cholangitis (PBC) using tolerizing immune modifying nanoparticles encapsulating PBC associated antigens.
    Type: Application
    Filed: October 21, 2022
    Publication date: December 12, 2024
    Inventors: John J. Puisis, Michael Boyne, Greta Wodarcyk, Adam Elhofy
  • Antibody and methods for selective inhibition of T-cell responses
    Patent number: 8968739
    Abstract: The present invention provides compositions, methods, and assays for treating an inflammatory and/or autoimmune disease, and/or transplanted tissue rejection using anti-?? TCR antibodies and antibody fragments. Anti-?? TCR antibodies are antibodies which bind to a ?? TCR. Anti-?? TCR antibodies produced by the hybridoma TOL101 MCB are also provided.
    Type: Grant
    Filed: July 19, 2013
    Date of Patent: March 3, 2015
    Assignee: Tolera Therapeutics, Inc.
    Inventors: Daniel R. Getts, James J. Herrmann, John J. Puisis, Frank J. Fokta
  • Antibody and methods for selective inhibition of T-cell responses
    Patent number: 8722049
    Abstract: The present invention provides compositions, methods, and assays for treating an inflammatory and/or autoimmune disease, and/or transplanted tissue rejection using anti-?? TCR antibodies and antibody fragments. Anti-?? TCR antibodies are antibodies which bind to a ?? TCR. Anti-?? TCR antibodies produced by the hybridoma TOL101 MCB are also provided. Methods for treatment of an inflammatory disease, an autoimmune disease and for tissue transplant rejection using therapeutic dosing regimen of anti-?? TCR antibodies and antibody fragments and for upregulating the numbers of Treg T-cells are also provided. The present invention also provides methods of treating inflammatory and/or autoimmune disease, and/or transplanted tissue rejection using a therapeutic amount of ex vivo expanded regulatory T-cells.
    Type: Grant
    Filed: June 28, 2013
    Date of Patent: May 13, 2014
    Assignee: Tolera Therapeutics, Inc.
    Inventors: Daniel R Getts, James J Herrmann, John J Puisis, Frank J Fokta
  • ANTIBODY AND METHODS FOR SELECTIVE INHIBITION OF T-CELL RESPONSES
    Publication number: 20130302301
    Abstract: The present invention provides compositions, methods, and assays for treating an inflammatory and/or autoimmune disease, and/or transplanted tissue rejection using anti-?? TCR antibodies and antibody fragments. Anti-?? TCR antibodies are antibodies which bind to a ?? TCR. Anti-?? TCR antibodies produced by the hybridomaTOL101 MCB are also provided. Methods for treatment of an inflammatory disease, an autoimmune disease and for tissue transplant rejection using therapeutic dosing regimen of anti-?? TCR antibodies and antibody fragments and for upregulating the numbers of Treg T-cells are also provided. The present invention also provides methods of treating inflammatory and/or autoimmune disease, and/or transplanted tissue rejection using a therapeutic amount of ex vivo expanded regulatory T-cells.
    Type: Application
    Filed: June 28, 2013
    Publication date: November 14, 2013
    Inventors: Daniel R. GETTS, James J. Herrmann, John J. Puisis, Frank J. Fokta
  • ANTIBODY AND METHODS FOR SELECTIVE INHIBITION OF T-CELL RESPONSES
    Publication number: 20130273089
    Abstract: The present invention provides compositions, methods, and assays for treating an inflammatory and/or autoimmune disease, and/or transplanted tissue rejection using anti-?? TCR antibodies and antibody fragments. Anti-?? TCR antibodies are antibodies which bind to a ?? TCR. Anti-?? TCR antibodies produced by the hybridomaTOL101 MCB are also provided. Methods for treatment of an inflammatory disease, an autoimmune disease and for tissue transplant rejection using therapeutic dosing regimen of anti-?? TCR antibodies and antibody fragments and for upregulating the numbers of Treg T-cells are also provided. The present invention also provides methods of treating inflammatory and/or autoimmune disease, and/or transplanted tissue rejection using a therapeutic amount of ex vivo expanded regulatory T-cells.
    Type: Application
    Filed: March 15, 2013
    Publication date: October 17, 2013
    Inventors: Daniel R. GETTS, James J. Herrmann, John J. Puisis, Frank J. Fokta
  • Antibody for selective inhibition of T-cell responses
    Patent number: 8524234
    Abstract: The present invention provides compositions, methods, and assays for treating an inflammatory and/or autoimmune disease, and/or transplanted tissue rejection using anti-?? TCR antibodies and antibody fragments. Anti-?? TCR antibodies are antibodies which bind to a ?? TCR. Anti-?? TCR antibodies produced by the hybridoma TOL101 MCB are also provided. Methods for treatment of an inflammatory disease, an autoimmune disease and for tissue transplant rejection using therapeutic dosing regimen of anti-?? TCR antibodies and antibody fragments and for upregulating the numbers of Treg T-cells are also provided.
    Type: Grant
    Filed: November 5, 2012
    Date of Patent: September 3, 2013
    Assignee: Tolera Therapeutics, Inc
    Inventors: Daniel R. Getts, James J. Herrmann, John J. Puisis, Frank J. Fokta